Peacock WF, Rafique Z, Vishnevskiy K, et al. - Researchers investigated the efficacy of sodium zirconium cyclosilicate (SZC), a novel, highly selective potassium binder, with insulin and glucose as hyperkalemia treatment in the emergency department (ED). In this exploratory, phase 2, multicenter, randomized, double‐blind, placebo‐controlled study, 70 adult ED patients with blood potassium ≥ 5.8 mmol/L were randomized 1:1 to receive SZC 10 g or placebo, up to three times during a 10‐hour period, with insulin and glucose. Outcomes of this pilot study suggested incremental benefit of providing SZC with insulin and glucose in the emergency treatment of hyperkalemia over insulin and glucose alone. At 2 hours, they observed a greater reduction in mean (±SD) sK+ from baseline with SZC vs placebo. Additional potassium‐lowering therapy due to hyperkalemia was required at 0 to 4 hours in a numerically lower proportion of patients in the SZC group vs placebo.